Clinical Trials Cosmetics Dermatology Trials 
XTalks
SEPTEMBER 14, 2022
Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. Many people choose to undergo non-invasive cosmetic procedures to prevent or reduce the appearance of signs of aging. Daxxify is effective, as safe as competitors, and has been well tolerated in clinical trials.
XTalks
JUNE 17, 2024
RELATED: Innovations and Clinical Trial Diversity in Medical Aesthetics: Insights from Dr. Stephanie Manson Brown, VP & Head of Clinical Development at Allergan Aesthetics – Xtalks Life Science Podcast Ep. These findings further affirm relabotulinumtoxinA’s enduring efficacy, initially observed in prior trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Olympian Clinical Research
JUNE 2, 2021
At OCR we’re committed to educating the public and raising awareness about diseases like eczema, so today we’re taking some time to walk you through everything you need to know about this common dermatology condition. Triggers can vary patient by patient, but some of the most common eczema triggers are: Cosmetic products. Fragrances.
The Pharma Data
NOVEMBER 4, 2020
. Initiated CTP-543 THRIVE-AA1 Phase 3 Trial in November 2020. The THRIVE-AA1 Phase 3 trial is a randomized, double-blind, placebo-controlled clinical trial of CTP-543 to evaluate hair regrowth using the Severity of Alopecia Tool (SALT) after 24 weeks of dosing in approximately 700 adult patients with moderate to severe alopecia areata.
XTalks
JULY 5, 2022
XTALKS WEBINAR: Diversity and Inclusion in Clinical Trials — Practical Steps for Patient Recruitment Strategies. Register for this free webinar to learn about the practical steps to be taken towards diversity and inclusion in clinical trials. The trial included 55 subjects over the age of 30 with a wrinkle score of ?2
XTalks
MAY 22, 2023
It’s an extremely important factor I consider in my therapeutic process of restoring their natural beauty and appearance,” said Macrene Alexiades, MD, PhD, dual US-EU board-certified dermatologist, SkinVive by Juvéderm lead investigator and author of the clinical trial published in Dermatologic Surgery.
The Pharma Data
MARCH 4, 2021
associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. “For patients who suffer from alopecia areata, it is not a cosmetic condition, it is a devastating autoimmune disease that can have significant psychological effects.
Expert insights. Personalized for you.
98 
Let's personalize your content